Cosmo Pharmaceuticals highlights study published in The Lancet demonstrating the effectiveness of GI Genius(TM) in colonoscopies Page 1

Dublin, Ireland–(Newsfile Corp. – September 2, 2024) – Cosmo Intelligent Medical Devices (Cosmo IMD), a division of Cosmo Pharmaceuticals NV (SIX: COPN) (FSE: C43) (“Cosmo”), developer and manufacturer of the GI Genius™ intelligent endoscopy system, is pleased to announce the publication of a landmark study in The Lancet. This study, entitled “Polyp detection with colonoscopy assisted by the artificial intelligence endoscopy module GI Genius™ compared with standard colonoscopy in routine colonoscopy practice (COLO-DETECT): a multicenter, open-label, parallel-arm, randomized controlled trial”represents a significant advance in the prevention and detection of colon cancer.

The COLO-DETECT study, conducted by a team of researchers including Alexander Seager, MSc, Prof. Linda Sharp, PhD, and Laura J. Neilson, MD, provides evidence of the effectiveness of the GI Genius™ system in improving polyp detection rates during colonoscopy. This multicenter, open-label study demonstrated that the use of GI Genius™ improved the detection of colorectal adenomas in an additional 8.3% of patients compared to standard colonoscopy procedures, potentially reducing the incidence of colorectal cancer.

“This publication is an important milestone not only for Cosmo Pharmaceuticals but also for the global medical communitysaid Gio Di Napoli, CEO of Cosmo Pharmaceuticals. “The GI Genius™ system, distributed exclusively by Medtronic worldwide, continues to prove its value in routine clinical practice by helping to achieve better outcomes for patients undergoing colonoscopy. We are proud to be at the forefront of innovation in AI-powered healthcare, and this study underscores our commitment to improving patient care through cutting-edge technology.”

The results of the study demonstrate the value of integrating AI into clinical routine to improve the accuracy and effectiveness of colorectal cancer screening. Since colorectal cancer is one of the leading causes of cancer-related death worldwide, improved detection of precancerous polyps is crucial for early intervention and prevention.

Cosmo Pharmaceuticals continues to support the medical community with innovative solutions such as GI Genius™ that exemplify the future of AI in healthcare. The company will continue to work closely with its distribution partner Medtronic to ensure this life-saving technology is accessible to healthcare providers worldwide.